Palvella Therapeutics (PVLA) EPS (Basic) (2016 - 2024)
Historic EPS (Basic) for Palvella Therapeutics (PVLA) over the last 12 years, with Q4 2024 value amounting to $0.12.
- Palvella Therapeutics' EPS (Basic) fell 2191.55% to $0.12 in Q4 2024 from the same period last year, while for Dec 2024 it was -$7.83, marking a year-over-year decrease of 693934.04%. This contributed to the annual value of -$7.83 for FY2024, which is 403637.24% down from last year.
- As of Q4 2024, Palvella Therapeutics' EPS (Basic) stood at $0.12, which was down 2191.55% from -$3.94 recorded in Q3 2024.
- Palvella Therapeutics' 5-year EPS (Basic) high stood at $3.63 for Q2 2023, and its period low was -$14.15 during Q1 2023.
- For the 5-year period, Palvella Therapeutics' EPS (Basic) averaged around -$1.44, with its median value being -$0.14 (2021).
- Within the past 5 years, the most significant YoY rise in Palvella Therapeutics' EPS (Basic) was 269285.71% (2023), while the steepest drop was 2011428.57% (2023).
- Quarter analysis of 5 years shows Palvella Therapeutics' EPS (Basic) stood at -$0.26 in 2020, then skyrocketed by 50.0% to -$0.13 in 2021, then grew by 15.38% to -$0.11 in 2022, then surged by 239.71% to $0.15 in 2023, then decreased by 21.92% to $0.12 in 2024.
- Its last three reported values are $0.12 in Q4 2024, -$3.94 for Q3 2024, and -$2.47 during Q2 2024.